Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Disease
- Therapeutic
- Pharmaceuticals
- Biotechnology
- Diagnostic
- Assay
- Immune
- Antibiotic
- Antibody
- DNA
- Vaccine
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 249
License Grant
The University hereby grant to Licensee, and Licensee hereby accepts, a license under Patent Rights to make and have made, to use and have used, to sell and have sold, to offer for sale, and to import and have imported Licensed Products and to practice Licensed Methods, in the Field within the Territory and during the Term.
License Property
The technology is titled Telomerase Reverse Transcriptase as Antigen for Immunization in Cancer and were made in the course of research at UCSD are covered by Patent Rights.
The inventions titled Cancer Immunotherapy and Diagnosis Using Universal Tumor Associated Antigens, Including hTERT, are covered by Patent Rights are covered by Patent Rights.
Field of Use
The technology is in the field of therapeutic and preventive cancer vaccines in humans.
IPSCIO Record ID: 4396
License Grant
Licensor hereby grants to Licensee and its Affiliates an exclusive, royalty-bearing sub-license under the Licensed Patents, including the right to grant further sublicenses solely to make, have made, use, import, sell, or have sold Licensed Products in the Territory under the Field of Use.
License Property
GRNVAC means the technology acquired by the Licensee under the Asset Contribution Agreement pertaining to the presentation of one or more antigens to the immune system using patient monocyte-derived (VAC-1) or dendritic cells or human embryonic stem cell-derived or induced pluripotent stem cell-derived antigen presenting cells (VAC-2).
018/062C
Genes for Human Telomerase Reverse Transcriptase and Telomerase Variants
US
09/438,486
12-Nov-99
6,927,285
018/181C
Telomerase
US
09/843,676
26-Apr-01
7,056,513
018/210C
Nucleic Acids Encoding Human Telomerase Reverse Transcriptase and Related Homologs
US
09/721,506
22-Nov-00
7,262,288
018/213C
Nucleic Acid Compositions for Eliciting an Immune Response Against Telomerase Reverse Transcriptase
US
10/044,692
11-Jan-02
7,560,437
018/221P
Human Telomerase Reverse Transcriptase Polypeptides
US
10/877,124
24-Nov-09
7,622,549
018/224C
Immunogenic Composition
US
11/894,643
20-Aug-07
Field of Use
Licensee has acquired Licensor’s technology directly related to the research, development and commercialization of products based on primate pluripotent embryonic stem cells.
Field of Use means use of telomerase as an antigen in an immunotherapeutic product for use in humans wherein the telomerase antigen is delivered using (i) patient monocyte-derived dendritic cells, or other patient blood or bone marrow-derived antigen presenting cells, (ii) human embryonic stem cell derived dendritic cells or other antigen presenting cells, or (iii) induced pluripotent stem cell derived dendritic cells or other antigen presenting cells.
IPSCIO Record ID: 28356
License Grant
University grants to Licensee an exclusive worldwide license under Patent Rights to make, have made, use lease, offer to sell, sell and import the Licensed Products within the Licensed Field for the term of this Agreement.
License Property
The Telomerase Assay is a patent-pending blood test for lung cancer.
Valuable inventions, comprised of the Patent Rights identified in Exhibit A-1, and generally known as 'Telomerase Assay of Body Fluids for Cancer Screening and Assessment of Disease Stage and Prognosis''('Inventions') have been made by UM Personnel
Field of Use
'Licensed Field' The use of Patent Rights for cancer diagnostics in all fields.
IPSCIO Record ID: 209511
License Grant
The University Licensor grants an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale the licensed products in the field. This license grant is exclusive except that the University may use and permit other not-for profit organizations to use the licensed patent rights for educational and research purposes.
License Property
The licensed property includes Live Recombinant Listeria Monocytogenes Vaccines and Production of Cytotoxic T-Cell Response, Use of Listeria as a Live Cancer Vaccine, Methods and Compositions for Immunotherapy of Cancer, Immunogcnic Compositions Comprising Aal/Dat Double Mutant Auxotrophic, Attenuated Strains of Listeria and Their Methods of Use, Method for Enhancing Immunogenicity of Antigens, Improved Cell-Mediated Immunity and Tumor Mediated Immunity with Listeriolysin (LLO), Method for Enhancing the lmmunogenicity of Antigens, Compositions and Methods for Enhancing the lmmunogenicity of Antigens and A Technique for Constructing Antibiotic-Resistance Free Vaccine Strains of L.Monocytogenes.
Field of Use
The field means therapeutic use in humans and other mammals. The primary strategic field shall be Cancer, including Cancer caused by infection. The secondary strategic field includes Infectious Disease, Allergy, Autoimmune Disease, and any other therapeutic indications.
IPSCIO Record ID: 249713
License Grant
Licensor grants to Licensee of the United Kingdom a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain any of the following two Licensed Antigens
• Any and all ANTIGENS expressed in Prostate Cancer
• Any and all ANTIGENS expressed in Breast Cancer.
In further consideration of the obligations assumed by Licensee and subject to the terms and conditions of this Agreement, as of May 22, 2002 Licensee grants a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain the following Licensed Antigens
• Any and all Antigens expressed in Lung Cancer
License Property
The Product shall mean any and all pharmaceutical compositions for Prophylactic Immunization and/or Therapeutic Immunization in the field comprising one or more of the Licensed Antigens in combination with Adjuvant as an ingredient or component in any formulation, configuration, combination and/or delivery system, in which Adjuvant induces, augments, fine-tunes or enhances the Antigen specific immune response of any of such Licensed Antigens contained within Product.
The patents relate to Nucleic Acid and lmmunostimulatory methods and processes.
Field of Use
The Field shall mean the use of Adjuvant in combination with Licensed Antigens as part of a Product and/or Combination for the purpose of inducing, augmenting, fine-tuning or enhancing in vivo, in vitro or ex vivo of an Antigen specific immune response and in all cases for Prophylactic Immunization and/or Therapeutic Immunization against Licensed Cancers in humans, excluding Specific Field.
Specific Field shall mean without limitation the use of Adjuvant in combination with DNA Vaccines or other than in combination with a Licensed Antigen and independently from a Licensed Antigen or in combination with antibodies in passive immunotherapy applications when not combined with a tumor Antigen; or in all non Antigen specific ex vivo applications or for all purposes other than eliciting, inducing, augmenting, fine-tuning or enhancing an Antigen-specific immune response.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
